Antibody response to Pneumocystis jirovecii major surface glycoprotein

Emerging Infectious Diseases

Volumn 12, Issue 8, 2006, Pages 1231-1237

  Daly, Kieran R ^a,b   Huang, Laurence ^c   Morris, Alison ^d   Koch, Judy ^a,b   Crothers, Kristina ^c,e   Levin, Linda ^b   Eiser, Shary ^c   Satwah, Supriya ^b   Zucchi, Patrizia ^c,f   Walzer, Peter D ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGAL PROTEIN; FUNGUS ANTIBODY; GPA PROTEIN, PNEUMOCYSTIS CARINII SP.; MEMBRANE PROTEIN;

ADULT; AIDS RELATED COMPLEX; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; MICROBIOLOGY; MIDDLE AGED; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODIES, FUNGAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNGAL PROTEINS; HIV INFECTIONS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PNEUMOCYSTIS JIROVECI; PNEUMONIA, PNEUMOCYSTIS;

EID: 33750583311     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1708.060230     Document Type: Article

References (30)

1. Redhead SA, Cushion MT, Frenkel JK, Stringer JR. Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J Eukaryot Microbiol. 2006;53:2-11.
2. Beard CB, Carter JL, Keely SP, Huang L, Pieniazek NJ, Moura IN, et al. Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerg Infect Dis. 2000;6:265-72.
3. Crothers K, Beard CB, Turner J, Groner G, Fox M, Morris A, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS. 2005;19:801-5.
4. Vargas SL, Hughes WT, Santolaya ME. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis. 2001;32:855-61.
5. Morris A, Sciurba FC, Githaiga A, Lebedeva I, Elliott WM, Hogg JC, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med. 2004;170:408-13.
6. Gigliotti F, Hughes WT. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest. 1988;81:1666-8.
7. Garvy BA, Wiley JA, Gigliotti F, Harmsen AG. Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect Immun. 1997;65:5052-6.
8. Zheng M, Shellito JE, Marrero L, Zhong Q, Julian S, Ye P, et al. CD4+ T cell-independent vaccination against Pneumocystis carinii in mice. J Clin Invest. 2001;108:1469-74.
9. Smulian AG, Walzer PD. Serological studies of Pneumocystis carinii infection. In: Walzer PD, editor. Pneumocystis carinii pneumonia. New York: Marcel Dekker; 1994. p. 141-51.
10. Walzer PD. Immunological features of Pneumocystis infection. In: Cushion MT, Walzer PD. Pneumocystis pneumonia. New York: Marcel Dekker; 2005. p. 451-78.
11. Peglow SL, Smulian GA, Linke MJ, Crisler J, Phair JWM, Gold J, et al. Serologic responses to specific Pneumocystis carinii antigens in health and disease. J Infect Dis. 1990;161:296-306.
12. Smulian AG, Sullivan D, Linke MJ, Halsey N, Quinn T, MacPhail AP, et al. Geographic variation in the humoral response to Pneumocystis carinii. J Infect Dis. 1993;167:1243-7.
13. Lundgren B, Lundgren JD, Nielsen T, Mathiesen L, Nielsen JO, Kovacs JA. Antibody responses to a major Pneumocystis carinii antigen in human immunodeficiency virus-infected patients with and without P. carinii pneumonia. J Infect Dis. 1992;165:1151-5.
14. Garbe TR, Stringer JR. Molecular characterization of clustered variants of genes encoding major surface antigens of human Pneumocystis carinii. Infect Immun. 1994;62:3092-101.
15. Mei Q, Turner RE, Sorial V, Klivington D, Angus CW, Kovacs JA. Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region. Infect Immun. 1998;66:4268-73.
16. Bishop LR, Kovacs JA. Quantitation of anti-Pneumocystis jiroveci antibodies in healthy persons and immunocompromised patient. J Infect Dis. 2003;187:1844-8.
17. Daly KR, Fichtenbaum C, Tanaka R, Linke MJ, Obert R, Thullen T, et al. Serologic responses to epitopes of the major surface glycoprotein of Pneumocystis jiroveci differ in human immunodeficiency virus-infected and uninfected persons. J Infect Dis. 2002;186:644-51.
18. Daly KR, Koch J, Levin L, Walzer PD. Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci. Emerg Infect Dis. 2004;10:848-54.
19. Kutty G, Kovacs JA. Asingle-copy gene encodes Kex1, a serine endoprotease of Pneumocystis jiroveci. Infect Immun. 2003;71:571-4.
20. Theus SA, Andrews RP, Stelle P, Walzer PD. Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat. J Clin Invest. 1995;95:2587-93.
21. Huang L, Stansell JD. AIDS and the lung. Med Clin North Am. 1996;80:775-801.
22. Malaspina A, Moir S, Orsega SM, Vasquez J, Miller NJ, Donoghue ET, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis. 2005;191:1442-50.
23. De Milito A. B lymphocyte dysfunctions in HIV infection. Curr HIV Res. 2004;2:11-21.
24. Jacobson MA, Khyam-Bashi H, Martin JN, Black D, Ng V. Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function. J Acquir Immune Defic Syndr. 2002;31:472-7.
25. D'Amico R, Yang Y, Mildvan D, Evans SR, Schnizlein-Bick CT, Hafner R, et al. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol. 2005;25:106-15.
26. Burns SM, Read JA, Yap PL, Brettle RP. Reduced concentrations of IgG antibodies to Pneumocystis carinii in HIV-infected patients during active Pneumocystis carinii infection and the possibility of passive immunization. J Infect. 1990;20:33-9.
27. Hofmann B, Odum N, Cerstoft J, Platz P, Ryder LP, Svjgaard A, et al. Humoral response to Pneumocystis carinii in patients with acquired immunodeficiency syndrome and in immunocompromised homosexual men. J Infect Dis. 1985;152:838-40.
28. Hofmann B, Nielsen PB, Odum N, Gerstoft J, Platz P, Ryder LP, et al. Humoral and cellular responses to Pneumocystis carinii, CMV, and herpes simplex in patients with AIDS and in controls. Scand J Infect Dis. 1988;20:389-94.
29. Elvin K, Bjorkman A, Heurlin N, Eriksson BM, Barkholt L, Linder E. Seroreactivity to Pneumocystis carinii in patients with AIDS verus other immunosuppressed patients. Scand J Infect Dis. 1994;26:33-40.
30. Laursen AL, Andersen PL. Low levels of IgG antibodies against Pneumocystis carinii among HIV-infected patients. Scand J Infect Dis. 1998;30:495-9.